Adamas Pharmaceuticals (ADMS) Coverage Initiated at Northland Securities

Equities research analysts at Northland Securities assumed coverage on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research report issued to clients and investors on Wednesday, MarketBeat reports. The firm set an “outperform” rating on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently commented on ADMS. Noble Financial upped their price target on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research note on Wednesday, October 4th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. Finally, Mizuho reissued a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $42.00.

Adamas Pharmaceuticals (NASDAQ ADMS) opened at $35.93 on Wednesday. Adamas Pharmaceuticals has a 1-year low of $13.50 and a 1-year high of $38.22. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.03). The company’s quarterly revenue was down 99.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.66) EPS. equities research analysts expect that Adamas Pharmaceuticals will post -3.87 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Adamas Pharmaceuticals in the third quarter valued at about $110,000. Quantbot Technologies LP bought a new position in Adamas Pharmaceuticals in the third quarter valued at about $119,000. Tower Research Capital LLC TRC bought a new position in Adamas Pharmaceuticals in the second quarter valued at about $109,000. Sei Investments Co. raised its stake in shares of Adamas Pharmaceuticals by 1,105.0% in the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock worth $185,000 after buying an additional 8,033 shares during the period. Finally, American International Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares during the period. Institutional investors own 79.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals (ADMS) Coverage Initiated at Northland Securities” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://sportsperspectives.com/2017/12/03/northland-securities-begins-coverage-on-adamas-pharmaceuticals-adms.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply